A Study of SHR-1210 Plus Apatinib in Patients With Soft Tissue Sarcoma

  • STATUS
    Recruiting
  • participants needed
    289
  • sponsor
    Jiangsu HengRui Medicine Co., Ltd.
Updated on 30 September 2022
measurable disease
kidney function tests
cancer chemotherapy
apatinib
soft tissue sarcoma
metastatic soft tissue sarcoma

Summary

The main purpose of this study is to evaluate the efficacy of SHR-1210 plus Apatinib versus AMD plus IFO in participants with soft tissue sarcoma.

Description

In this study, patients are randomly assigned in a 1:1 ratio to receive SHR-1210 plus Apatinib (SHR-1210 treatment up to 2 years) or ADM plus IFO 6 cycles. Randomisation balances patients by ECOG performance status (0 vs 1-2), histological tumour type and chemotherapy history. Tumour response is assessed every 6 weeks according to the Response Evaluation Criteria in Solid Tumours, version 1.1. Survival is assessed every 2 months until study completion. Blood samples are collected for pharmacokinetic and immunogenic analyses. Safety is assessed for all patients who received at least one dose of study treatment. Adverse events and clinical laboratory toxicity are graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0.

Details
Condition Sarcoma
Treatment SHR-1210 Plus Apatinib, ADM Plus IFO or IFO Alone
Clinical Study IdentifierNCT03711279
SponsorJiangsu HengRui Medicine Co., Ltd.
Last Modified on30 September 2022

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note